|
Wednesday, November 16, 2022
Print Current Session:
 |
|
|
Wednesday
SESSION 24:
NEW DEVELOPMENTS IN ATHERECTOMY, STENTS (UNCOATED, COATED AND BIORESORBABLE) [ALL TALKS ARE 5 MINUTES]
|
|
| SESSION 24 SCHEDULE | |
| PROGRESS IN ATHERECTOMY | |
| 7:53 AM - 7:58 AM | New Developments In Laser Atherectomy: What Makes It Different: When Is It Beneficial With Certainty |
|
Presenter(s):George L. Adams, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 7:59 AM - 8:04 AM | Index Atherectomy Interventions For Intermittent Claudication Are Associated With Higher Reintervention Rates Than Other Endovascular Treatments: Is This Device Specific |
|
Presenter(s):Caitlin W. Hicks, MD, MS Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:05 AM - 8:10 AM | Update On Optical Coherence Tomography (OCT) Guided Atherectomy (Pantheris) For In Stent Restenosis (ISR): Why It Is More Effective Treatment: From The INSIGHT Trial |
|
Presenter(s):Todd R. Vogel, MD, MPH Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:11 AM - 8:16 AM | Current Role Of Atherectomy In Treating Lower Extremity CLTI: A Vascular Surgeon’s View |
|
Presenter(s):James F. McKinsey, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| UPDATE ON THE SUPERA STENT | |
| 8:17 AM - 8:22 AM Power Point Presentation with Synched Audio |
Update On The Advantages Of The Supera Vasculomimetic (VMI) Stent For Treating Long Complex Fempop Occlusive Lesions: Is There Value To DCB Vessel Prep First |
|
Presenter(s):Peter C.J. Goverde, MD Location: Grand Ballroom East, 3rd Floor |
|
| 8:23 AM - 8:28 AM | The Supera Interwoven Stent: When Is It The Best Treatment And How To Optimally Deploy This Unique Stent |
|
Presenter(s):D. Christopher Metzger, MD / Craig M. Walker, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| DRUG ELUTING STENTS (DESs) FOR BTK LESIONS | |
| 8:29 AM - 8:34 AM | Updated 10-Year Experience With Everolimus DESs To Treat Long Infrapopliteal Lesions Causing CLTI: Indications, Results, Value And Limitations |
|
Presenter(s):Robert A. Lookstein, MD, MHCDL, FSIR, FAHA Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:35 AM - 8:40 AM | Bioresorbable Everolimus DESs To Treat BTK Lesions Causing CLTI: Promising Results Up To 5-7 Years: From The DISAPEAR Registry And A Meta-Analysis Of The Absorb Stent From Abbott |
|
Presenter(s):Steven Kum, MD / Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed (ClinEpi) Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:41 AM - 8:46 AM | An Update Of Long-Term Outcomes For Drug-Eluting Resorbable Scaffolds Below-The-Knee (BTK) And Progress Of The LIFE-BTK Trial With The Esprit Stent From Abbott |
|
Presenter(s):Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed (ClinEpi) / Sahil A. Parikh, MD / Brian G. DeRubertis, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:47 AM - 8:52 AM | Update On A 3-French Compatible Microstent (From Micro Medical) For Antegrade Or Retrograde Insertion To Treat Tibial Artery Lesions: The STAND And HEAL Trials |
|
Presenter(s):Robert E. Beasley, MD, FSIR, FSCAI Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:53 AM - 9:00 AM | Panel Discussion |
| END OF SESSION 24 | |
| previous | next |